Press coverage about MyoKardia (NASDAQ:MYOK) has trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. MyoKardia earned a news impact score of 0.04 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 47.5047126702393 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Q2 2018 EPS Estimates for MyoKardia (MYOK) Lifted by Wedbush (americanbankingnews.com)
- MyoKardia prices common stock offering (seekingalpha.com)
- MyoKardia’s (MYOK) Buy Rating Reiterated at Cowen (americanbankingnews.com)
- Zacks: Analysts Anticipate MyoKardia (MYOK) Will Post Quarterly Sales of $6.32 Million (americanbankingnews.com)
- MyoKardia finalizes design of late-stage study of mavacamten in oHCM; shares down 9% (seekingalpha.com)
A number of analysts have recently issued reports on the stock. BidaskClub raised shares of MyoKardia from a “sell” rating to a “hold” rating in a research note on Wednesday. ValuEngine raised shares of MyoKardia from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Cowen reaffirmed a “buy” rating and set a $73.00 target price on shares of MyoKardia in a research note on Tuesday. Zacks Investment Research raised shares of MyoKardia from a “hold” rating to a “buy” rating and set a $59.00 target price for the company in a research note on Tuesday, March 13th. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and set a $70.00 target price on shares of MyoKardia in a research note on Friday, April 13th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $67.29.
MyoKardia (NASDAQ:MYOK) last posted its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.21). The company had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $7.82 million. MyoKardia had a negative net margin of 235.47% and a negative return on equity of 25.18%. equities analysts predict that MyoKardia will post -1.72 EPS for the current fiscal year.
In other MyoKardia news, insider Anastasios Gianakakos sold 3,000 shares of the stock in a transaction on Monday, March 5th. The shares were sold at an average price of $61.07, for a total transaction of $183,210.00. Following the completion of the transaction, the insider now owns 77,390 shares in the company, valued at $4,726,207.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jake Bauer sold 1,519 shares of the stock in a transaction on Thursday, May 3rd. The shares were sold at an average price of $48.95, for a total transaction of $74,355.05. Following the transaction, the insider now owns 62,125 shares of the company’s stock, valued at approximately $3,041,018.75. The disclosure for this sale can be found here. Insiders have sold 20,683 shares of company stock valued at $1,102,481 over the last ninety days. 33.40% of the stock is currently owned by corporate insiders.
MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression.
Receive News & Ratings for MyoKardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia and related companies with MarketBeat.com's FREE daily email newsletter.